Skip to main content
SpringerLink
Log in

Foreword

  • Published:
Drugs Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Rabe KF, Hurd S, Anzueto A, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2007; 176(6): 532–55

    Article  PubMed  Google Scholar 

  2. Lopez AD, Murray CC. The global burden of disease, 1990–2020. Nat Med 1998; 4(11): 1241–3

    Article  PubMed  CAS  Google Scholar 

  3. Mannino DM, Buist AS. Global burden of COPD: risk factors, prevalence, and future trends. Lancet 2007; 370(9589): 765–73

    Article  PubMed  Google Scholar 

  4. Calverley PMA, Anderson JA, Celli B, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007; 356(8): 775–89

    Article  PubMed  CAS  Google Scholar 

  5. Tashkin DP, Celli B, Senn S, et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med 2008; 359(15): 1543–54

    Article  PubMed  CAS  Google Scholar 

  6. Rennard S, Carrera M, Agusti AG. Management of chronic obstructive pulmonary disease: are we going anywhere? Eur Respir J 2000; 16(6): 1035–6

    Article  PubMed  CAS  Google Scholar 

  7. Whittemore AS, Perlin SA, DiCiccio Y. Chronic obstructive pulmonary disease in lifelong nonsmokers: results from NHANES. Am J Public Health 1995; 85(5): 702–6

    Article  PubMed  CAS  Google Scholar 

  8. Celli BR, Halbert RJ, Nordyke RJ, et al. Airway obstruction in never smokers: results from the Third National Health and Nutrition Examination Survey. Am J Med 2005; 118(12): 1364–72

    Article  PubMed  Google Scholar 

  9. Rabe KF. Treating COPD: the TORCH trial, P values, and the dodo. N Engl J Med 2007; 356(8): 851–4

    Article  PubMed  CAS  Google Scholar 

  10. Barnes PJ, Ito K, Adcock IM. Corticosteroid resistance in chronic obstructive pulmonary disease: inactivation of histone deacetylase. Lancet 2004; 363(9410): 731–3

    Article  PubMed  CAS  Google Scholar 

  11. Agusti AG. COPD, a multicomponent disease: implications for management. Respir Med 2005; 99(6): 670–82

    Article  PubMed  CAS  Google Scholar 

  12. Compton CH, Gubb J, Nieman R, et al. Cilomilast, a selective phosphodiesterase-4 inhibitor for treatment of patients with chronic obstructive pulmonary disease: a randomised, dose-ranging study. Lancet 2001; 358(9278): 265–70

    Article  PubMed  CAS  Google Scholar 

  13. Gamble E, Grootendorst DC, Brightling CE, et al. Antiinflammatory effects of the phosphodiesterase-4 inhibitor cilomilast (Ariflo) in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2003; 168(8): 976–82

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Hospital Universitari Son Dureta, Palma de Mallorca, Spain

    Alvar Agusti

Authors
  1. Alvar Agusti
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Agusti, A. Foreword. Drugs 68 (Suppl 2), 1–2 (2008). https://doi.org/10.2165/0003495-200868002-00001

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/0003495-200868002-00001

Search

Navigation